PubMed Health⌕ Search

Biomedical subjects

R Jorde

Publications and source records attributed to R Jorde.

At least 19 recordsLinked to original sources
PubMed2006

Blood pressure in relation to serum thyrotropin: The Tromsø study.

It appears to be an association between hypothyroidism and hypertension. However, the relation between thyroid function and blood pressure within the normal serum thyrotropin (TSH) range is uncertain. In the fifth Tromsø study, which is a population-based health survey, serum TSH and blood pressure were measured. This gave us the opportunity to test the hypothesis of a relation between serum TSH and blood pressure within the normal serum TSH range. In all 5872 subjects (2623 male subjects) not using blood pressure or thyroxine medication were included in the present study. Within the normal serum TSH range (0.20-4.00 mIU/l), there was a significant and positive relation between serum TSH and both systolic and diastolic blood pressure. Within this range, and adjusted for age, body mass index and smoking status, the systolic blood pressure was 1.4 mm Hg and the diastolic 1.6 mm Hg higher in male subjects in the highest versus those in the lowest serum TSH quartile. The corresponding differences in the female subjects were 4.0 and 2.7 mm Hg, respectively. When dividing this cohort in those with systolic (>160 mm Hg) and diastolic (>95 mm Hg) hypertension, serum TSH was higher in the hypertensive subjects, but the differences were only statistically significant for diastolic hypertension (serum TSH 1.88+/-0.82 versus 1.69+/-0.74 mIU/l for male subjects, and 1.79+/-0.78 versus 1.63+/-0.75 mIU/l for female subjects, P < 0.05). In conclusion, there is a modest, but significant positive association between serum TSH and blood pressure within the normal serum TSH range.

Adult↗
PubMed2006

The relationship between blood pressure and serum parathyroid hormone with special reference to urinary calcium excretion: the Tromsø study.

The aim of the present cross-sectional epidemiological study from Tromsø, Northern Norway, was to evaluate the relation between blood pressure and serum PTH, and to examine whether this relation can be explained by a blood pressure-induced increase in urinary calcium. Ten thousand-four hundred and nineteen subjects were invited to participate and 8,128 attended. Those with serum calcium outside the reference range (2.20-2.60 mmol/l), with increased serum creatinine (upper limit 120 micromol/l for men and 100 micromol/l for women) and those using antihypertensive medication were excluded. Three thousand- six hundred and twenty subjects had complete data on outcome measures. Height, weight, blood pressure, serum calcium, PTH, and creatinine were measured and smoking status recorded. A morning urine sample was collected and urinary calcium, sodium and creatinine measured. The urinary calcium/urinary creatinine ratio (Uca/Ucr) and urinary sodium/urinary creatinine ratio (Una/Ucr) were calculated. There was a significant association between both systolic and diastolic blood pressure and serum PTH. The Uca/Ucr increased with increasing blood pressure. However, the Uca/Ucr did not affect the association between blood pressure and serum PTH in a multiple linear regression model. The relationship between blood pressure and serum PTH was also seen in subjects with similar Uca/Ucr, and a negative association between serum PTH and the Uca/Ucr was found. In conclusion, blood pressure and serum PTH are associated. This association cannot be explained by the urinary calcium excretion alone.

Aged↗
PubMed2006

Screening for diabetes using HbA1c in elderly subjects.

The objective of the study was to determine the prevalence of known diabetes among elderly subjects receiving nursing care in a north Norwegian population, to screen for new cases using HbA1c measurement and to evaluate the quality of care for those with diabetes. Men and women, with and without known diabetes, above 69 years and receiving nursing care either in an institution or in their own home in the municipality of Tromsø, were included. A health questionnaire was administered and HbA1c measured. An oral glucose tolerance test (OGTT) was performed in those with HbA1c > 6.5% (upper reference limit). A total of 788 subjects were evaluated for participation and 228 completed the study. Forty-six subjects (20.2%) had a previous diagnosis of diabetes. Their age was 80.1+/-5.9 years (mean+/-SD) and HbA1c level 7.6+/-1.4%. Most patients had their blood glucose measured weekly and 65% used blood pressure medication; on average they were seen by their private doctor four times a year and annually by an ophthalmologist. Six subjects with undiagnosed diabetes had HbA1c > 6.5%. Diabetes was confirmed in one, excluded in two and further testing declined in three. None of these six subjects had HbA1c > 7.0%. In conclusion, there is a high prevalence of diabetes among elderly subjects needing nursing care. The prevalence of undiagnosed diabetes in need of treatment, as evaluated by the HbA1c level, was low, indicating that the focus on diabetes and quality of care for the elderly in our area is fairly good.

Aged↗
PubMed2006

Serum TSH is positively associated with BMI.

OBJECTIVE: To investigate whether there is an association between serum thyroid-stimulating hormone (TSH) within the normal range and body mass index (BMI). DESIGN AND SUBJECTS: The study was performed in 6164 subjects (2813 males) who attended the fifth Tromsø study in 2001, and in 1867 subjects (873 males) that attended both the fourth Tromsø study in 1994/1995 as well as the fifth Tromsø study. MEASUREMENTS: Height, weight, and serum TSH were measured in all subjects, and smoking status was recorded. RESULTS: Smokers and nonsmokers were analyzed separately. In the fifth Tromsø study, serum TSH was positively and significantly associated with BMI in the nonsmokers. Within the normal TSH range (defined as the 2.5-97.5 percentile), nonsmoking males in the highest TSH quartile had a mean BMI 0.4 kg/m(2) higher compared to those in the lower quartile, whereas the difference for nonsmoking women was 1.4 kg/m(2). Similarly, in nonsmokers in the longitudinal study, there was a significant and positive association between delta serum TSH (serum TSH in 2001 minus serum TSH in 1994) and delta BMI in those with serum TSH within the normal range both in 1994 and 2001. In these subjects, the quartile with the highest delta serum TSH had a mean increase in BMI from 1994 to 2001 that was 0.3 kg/m(2) higher compared to those in the quartile with the lowest delta serum TSH. For the smokers, relations between serum TSH and BMI were not statistically significant. CONCLUSION: In nonsmokers there is a positive association between serum TSH within the normal range and BMI.

Adult↗
PubMed2006

Serum TSH levels in smokers and non-smokers. The 5th Tromsø study.

BACKGROUND: Cigarette smoking has a number of effects on the thyroid gland including the development of Graves' disease and thyroid multinodularity. However, the effect of smoking on thyroid function is more uncertain. PATIENTS AND METHODS: The present cross-sectional study included 6,085 subjects (1,744 smokers) without thyroxine medication and 441 subjects (92 smokers) with thyroxine medication that attended the 5th Tromsø study in 2001, and 460 subjects (114 smokers) that attended follow-up studies after the 5th Tromsø study. Serum TSH was measured in the 5th Tromsø study, and serum TSH, free T4, and free T3 in the follow-up studies. Comparisons between smokers and non-smokers were performed with a general linear model with age, BMI, (and gender) as covariables. RESULTS: Serum TSH levels were significantly lower in the smokers than in the non-smokers, both in males (1.63 +/- 0.88 vs. 1.95 +/- 1.04 mIU/L [p < 0.01]), and in females (1.55 +/- 0.86 vs. 1.86 +/- 1.01 mIU/L [p < 0.01]). Serum free T4 and free T3 levels were significantly higher in smokers than non-smokers (14.0 +/- 2.2 vs. 13.4 +/- 2.4 pmol/L for free T4 [p < 0.05], and 3.89 +/- 0.79 vs. 3.72 +/- 0.67 pmol/L for free T3 [p < 0.01], males and females analyzed together). There was no association between number of cigarettes smoked and the serum TSH level. CONCLUSION: Smokers have lower serum TSH and higher free T4 and free T3 levels than non-smokers, which may be of importance when evaluating subjects with subclinical hypothyroidism.

Adult↗
PubMed2006

Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study.

OBJECTIVE: To evaluate the relation between serum thyroid-stimulating hormone (TSH) and lipids. DESIGN: Cross-sectional epidemiological study, nested case-control study, and a placebo-controlled double-blind intervention study. METHODS: In the 5th Tromsø study serum TSH, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured. Subjects with subclinical hypothyroidism (SHT) and a matching control group were re-examined and apolipoprotein A1 (Apo A1) and apolipoprotein B (Apo B) were also measured. Subjects with SHT were included in an intervention study with thyroxine supplementation for 1 year. RESULTS: A total of 5143 subjects from the 5th Tromsø study were included. A significant and positive correlation between serum TSH levels and serum TC and LDL-C levels were found in both genders. However, in the females this did not reach statistical significance after adjusting for age and BMI. The serum LDL-C were significantly higher and the Apo A1 levels significantly lower in 84 SHT subjects compared with 145 controls, and in the SHT females the TC levels were also significantly elevated. In the intervention study (32 subjects given thyroxine and 32 subjects given placebo), we observed a significant reduction in the Apo B levels after thyroxine medication. In those that at the end of the study had serum TSH levels in the range 0.2-2.0 mIU L(-1), the serum TC and LDL-C levels were also significantly reduced. CONCLUSIONS: There is a positive association between serum TSH levels and TC and LDL-C levels. These lipid levels are reduced with thyroxine treatment in subjects with SHT.

Adult↗
PubMed2005

Coeliac disease in subjects with secondary hyperparathyroidism.

OBJECTIVE: Coeliac disease (CD) may present in its classical form with diarrhoea and weight loss, but also with atypical symptoms that are both related and unrelated to malabsorption. Osteomalacia or osteopenia following malabsorption of calcium and vitamin D is known to occur in patients with CD, and in such cases secondary hyperparathyroidism (SHP) caused by low serum calcium levels is frequently found. However, the prevalence of CD in subjects with SHP has not been reported. MATERIAL AND METHODS: In the Tromsø study 2001, serum parathyroid hormone (PTH) and calcium were measured in 7954 subjects of whom 6061 were eligible for follow-up. From this group, 97 subjects with SHP (serum PTH> or =6.5 pmol/l and serum calcium <2.40 mmol/l) and 104 matched control subjects were re-examined with serological tests for CD (anti-tissue transglutaminase, anti-gluten IgA and IgG). RESULTS: CD was diagnosed in 4 subjects, all from the original SHP group. At the re-examination, only 29 of the 97 subjects with SHP still had elevated serum PTH levels. Among these were 3 of the subjects with CD. When grouping the serological test results as negative, borderline or positive, there was a significant difference between the SHP group and the controls for anti-tissue transglutaminase and anti-gluten IgA (p<0.05). CONCLUSIONS: Subjects with SHP, at least when SHP is persistent, should be tested for CD.

Adult↗
PubMed2005

Effects of acute hypercalcaemia on blood pressure in subjects with and without parathyroid hormone secretion.

AIM: Acute hypercalcaemia increases the blood pressure, but the mechanism is uncertain. It may partly be the result of the concomitant fall in parathyroid hormone (PTH) secretion as PTH has been reported to have a vasodilator effect. To elucidate this, we infused calcium intravenously in subjects with and without PTH secretion. METHODS: Seven thyroparathyroidectomized subjects with undetectable PTH levels and 10 controls were studied twice, once with a calcium clamp technique that increased plasma ionized calcium in two steps of 0.1 mmol L(-1), each step lasting 60 min, and once with a placebo infusion. RESULTS: On the placebo day, blood pressure and all other variables were unaffected in both groups. On the calcium day, systolic blood pressure increased gradually and significantly from end of baseline till end of the calcium infusion in the controls (123.5 +/- 19.8 and 134.2 +/- 17.6 mmHg, P < 0.004) but not in the thyroparathyroidectomized subjects (124.9 +/- 15.7 and 126.0 +/- 20.6 mmHg, P = ns). Serum PTH levels fell promptly in the controls, and in both groups there was a significant increase in serum phosphate. The diastolic blood pressure and pulse rate, and the plasma adrenaline and noradrenaline, plasma renin activity, and serum aldosterone levels were unaffected by the calcium infusion. CONCLUSION: During acute hypercalcaemia the blood pressure increase appears unrelated to catecholamine secretion and the renin-aldosterone system, whereas the fall in PTH secretion may play a contributory role.

Adult↗
PubMed2005

Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The fifth Tromsø study.

OBJECTIVE: Smoking is associated with reduced bone density and calcium absorption, and reduced serum levels of vitamin D. A compensatory increase in serum parathyroid hormone (PTH) would therefore be expected as a result of an altered calcium balance. However, reports on PTH levels in smokers are conflicting. As serum PTH levels give important information on the calcium balance, the PTH levels in smokers are of interest. SUBJECTS AND METHODS: In the fifth Tromsø study, smoking status was recorded and serum PTH measured in 7896 subjects. Intakes of calcium and vitamin D were evaluated with a food-frequency questionnaire. In a follow-up study on 205 subjects, serum 25-hydroxyvitamin D, calcium absorption, and renal excretion of calcium were measured in addition. RESULTS: The serum PTH levels were significantly lower in smokers than non-smokers (3.1+/-1.4 vs 3.6+/-1.9 pmol/l in males; 3.1+/-1.5 vs 3.6+/-1.8 pmol/l in females (P < 0.001) after correcting for confounding variables, linear regression). In the smokers, there was no association between number of cigarettes smoked and serum PTH. One year after quitting smoking, serum PTH levels were similar to those of people who had never smoked. The smokers had significantly lower intake of vitamin D, lower serum levels of 25-hydroxyvitamin D and lower calcium absorption. The intake of calcium and the renal excretion of calcium were similar to that in non-smokers. CONCLUSIONS: Smokers have lower serum PTH levels than non-smokers. This cannot be explained by the predictors of serum PTH measured in our study.

Adult↗
PubMed2004

Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial.

The aim of this study was to assess the effect of a low-dose testosterone on body composition and pulmonary function, as well as on quality of life, sexuality, and psychological symptoms in patients with chronic obstructive pulmonary disease (COPD). Twenty-nine men with moderate to severe COPD were allocated to receive either 250 mg of testosterone or placebo intra-muscularly, every fourth week, during the 26 weeks study period. Fat-free mass increased in the treatment group (P<0.05), and a significant difference between the treatment and the control group was seen after 26 weeks (P<0.05). Fat mass decreased in the treatment group (P<0.05), and there was a significant difference between the treatment and the control group after 12 weeks (P<0.01). A significantly better erectile function was reported in the treatment group at the final visit (P<0.05), and the overall sexual quality of life was significantly better in the treatment group after 12 weeks (P<0.05). No improvement in pulmonary function was found. In conclusion, administration of a low-dose testosterone to men with COPD for 26 weeks was associated with improvement of body composition, better erectile function and sexual quality of life. Furthermore, there were no clinical or biochemical side effects.

Absorptiometry, Photon↗
PubMed2004

The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study.

OBJECTIVES: Low levels of endogenous testosterone have been associated with increased risk of cardiovascular disease and atherosclerosis in men. Long-term hyperglycemia, as measured by glycosylated hemoglobin (HbA1c), is related to cardiovascular mortality, and HbA1c across its normal range is also positively related to coronary heart and cardiovascular disease mortality in men. We therefore undertook an analysis of the cross-sectional associations of total testosterone and SHBG levels with HbA1c levels, in a general population of 1419 men aged 25-84. METHODS: Total testosterone, sex hormone-binding globulin (SHBG) and HbA1c were measured by immuno-assay. Partial correlation and multiple regression analyses were used to estimate the associations between total testosterone and SHBG with HbA1c. Analyses of variance and covariance were used to compare men with or without diabetes. RESULTS: In age-adjusted partial correlation HbA1c was inversely associated with total testosterone (p<0.01) and SHBG (p<0.001). HbA1c was positively associated with body mass index (BMI) and waist circumference (WC) (p<0.001). In multiple regression analyses total testosterone, SHBG, age, number of cigarettes smoked, BMI and WC were independently associated with HbA1c levels. Men with a history of diabetes had lower levels of total testosterone in age-adjusted analyses (p<0.05) and lower levels of SHBG in both age- and WC-adjusted analyses (p<0.001 and p<0.01, respectively). CONCLUSION: Lower levels of total testosterone and SHBG were associated with increased HbA1c levels and diabetes independent of concomitant variations in obesity and body fat distribution.

Adult↗
PubMed2003

Effect of calcium supplementation on blood pressure in patients with secondary hyperparathyroidism.

The aim was to study the effect of calcium supplementation 477 mg twice daily on BP in patients with secondary hyperparathyroidism during an intervention study (6 weeks) and after 954 mg during a short study (3 h). The intervention study was a placebo-controlled, double-blind, cross-over, while the short study gave a placebo and calcium in random order on separate days. The participants were obtained from an epidemiological survey in Tromsø 1994-1995 that included more than 27.000 subjects. The re-examination was performed in 2000/2001 at the University Hospital of North Norway, Norway. There were 18 subjects with secondary hyperparathyroidism and 28 control subjects in the intervention study while there were 14 cases and 8 control subjects in the short study. The results showed that in the subjects with secondary hyperparathyroidism after calcium supplementation in the intervention study there was an increase in serum calcium from 2.28 +/- 0.09 to 2.36 +/- 0.06 mmol/l (mean +/- SD) and a decrease in serum PTH from 8.6+/-1.6 to 6.5+/-2.4 pmol/l. However, there was no significant difference in either systolic or diastolic BP between calcium supplementation and placebo (138.3 +/- 21.0 vs 135.9 +/- 17.0 mm Hg and 80.9 +/- 11.1 vs 78.9+/-9.5 mm Hg, respectively). Similar results were seen in the control group. In the short study, serum calcium increased and serum PTH decreased after oral calcium, but the BP did not differ as compared to when placebo was given. To conclude, in the present setting we did not find any effect on BP by calcium supplementation in subjects with moderate secondary hyperparathyroidism.

Aged↗
PubMed2003

Parathyroid hormone and left ventricular hypertrophy.

AIMS: A relation between left ventricular hypertrophy and parathyroid hormone (PTH) has been described in patients with end stage renal disease and secondary hyperparathyroidism. In vitro studies indicate a hypertrophic effect of PTH on cardiomyocytes. The purpose of this study was to examine the relation between PTH and left ventricular hypertrophy in a general population. METHODS AND RESULTS: The fourth Tromsø study (1994-1995) included 27159 subjects. 2700 had serum PTH measurement and left ventricular mass by height (LVMH) estimated with M-mode echocardiography. Among these, 980 males and 1060 females were without known cardiovascular disease or valvular heart disease and did not use blood pressure medication. In this group, using a multiple linear regression model, body mass index (BMI), followed by systolic blood pressure, were found to be the strongest predictors of LVMH. In males older than 59 years and females younger than 60 years, PTH was a significant and positive predictor of LVMH (P<0.05). The relation between PTH and LVMH was not linear. There was a sharp increase in LVMH (both unadjusted and adjusted for age, BMI, and systolic blood pressure) in the upper PTH percentiles with the breaking point being the 95 percentile for men and the 98 percentile for women. Subjects in these upper PTH ranges had 12-17% higher adjusted LVMH than those in the lower 10% of the PTH range. This effect was not related to serum calcium level. If examining separately those with PTH levels within +/-2SD from the mean, no relation between PTH and LVMH was found. CONCLUSIONS: PTH is an independent predictor of LVMH in males older than 59 years and females younger than 60 years. This effect is only seen when PTH is substantially elevated and may then be involved in cardiac pathophysiology.

Adult↗
PubMed2001

Determinants of serum calcium in men and women. The Tromsø Study.

The level of serum calcium appears to be associated with blood pressure and metabolic risk factors for cardiovascular disease. Determinants of serum calcium may therefore be of interest. In a health survey in Tromsø in 1994-1995, 27,159 subjects were examined. The survey included measurements of serum calcium and questionnaires on diet and lifestyle factors. In males mean serum calcium declined from 2.41 mmol/l for those in their 20s to 2.34 mmol/l for those in their 80s. In females mean serum calcium was stable at a level of 2.35 mmol/l before the menopause, and thereafter reached a plateau of 2.39 mmol/l. In both sexes serum calcium showed a positive association with body mass index (BMI) and coffee consumption that persisted after correcting for other variables in a multiple regression model (p < 0.05). Physical activity had no significant association with serum calcium. In females alcohol consumption was negatively, and cigarette smoking positively associated with serum calcium (p < 0.01). No significant effect on the serum calcium levels was found for the intake of calcium or vitamin D, except for males with a calcium intake below 200 mg/day. Some of the observed effects, like the variation with age, may partly be explained by alterations in levels of serum albumin to which approximately 40% of circulating calcium is bound and which was not adjusted for in this study, whereas that is hardly the case for the association with BMI and coffee consumption. However, none of these factors could affect the serum calcium level more than 0.02 mmol/l, and the biological significance of the observed associations questionable.

Adult↗
PubMed2000

Primary hyperparathyroidism detected in a health screening. The Trømsø study.

Serum calcium was measured in 12,339 men and 13,394 women ages 25 to 75. Primary hyperparathyroidism, defined as a combination of serum calcium and parathyroid hormone (PTH) levels within the extreme or upper normal range, was diagnosed in 17 men and 47 women. The prevalence in both sexes increased with age. When 42 subjects with asymptomatic primary hyperparathyroidism were followed for 3 years, no significant increase in serum calcium or PTH was seen. In a subgroup of 473 men and 517 women ages 50 to 75, serum PTH was measured along with serum calcium. Depending on the criteria used to define primary hyperparathyroidism, the prevalence in older women within this subgroup ranged from 3.6% to 13.9%. The study concluded that a high prevalence of primary hyperparathyroidism exists in older women, although the progression of the disease, judging by serum calcium and PTH measurements, appears to be very slow.

Adult↗
PubMed2000

Bone mineral density and blood pressure in patients with asymptomatic hyperparathyroidism. The Tromsø Study.

OBJECTIVE: To evaluate bone mineral density and blood pressure in asymptomatic hyperparathyroidism. DESIGN: A case-control study. SETTING: The participants obtained from an epidemiological survey in Tromso 1994-95, that included more than 27 000 subjects. The re-examination in 1998 was performed at the University Hospital of Tromso, Norway. Participants. Thirty-nine subjects with hyperparathyroidism and 72 control subjects were studied. MAIN OUTCOME MEASURES: Bone mineral density measurements of the lumbar spine and the proximal femur (femoral neck, Ward's triangle, and trochanter). Systolic and diastolic blood pressure. RESULTS: In the hyperparathyroidism group bone mineral density was significantly lower measured at the lumbar spine (1.000 +/- 0.181 vs. 1.079 +/- 0. 194 g cm-2, mean +/- SD, P < 0.01) and at the femoral neck (0.806 +/- 0.121 vs. 0.852 +/- 0.141 g cm-2, P < 0.05). In the females, but not in the males, blood pressure was significantly higher in the hyperparathyroidism group than in the control group [systolic blood pressure 146.7 +/- 18.6 vs. 137.4 +/- 23.0 mmHg (P < 0.05) and diastolic blood pressure 88.1 +/- 11.8 vs. 82.2 +/- 10.6 mmHg (P < 0. 05)]. In the females the number of subjects on antihypertensive medication was significantly higher in the hyperparathyroidism group than in the control group (32.1% and 16.6%, respectively, P < 0.01). CONCLUSIONS: Subjects with asymptomatic hyperparathyroidism have moderately reduced bone mineral density. In females with hyperparathyroidism there is an increase in blood pressure.

Adult↗